Le Lézard
Classified in: Health
Subject: SVY

NEW REPORT: U.S. CBD Sales in General Retail Forecast to Approach $13 Billion by 2024, More Than Double Dispensary CBD Sales


OAKLAND, Calif., Sept. 12, 2019 /CNW/ -- The growing popularity and mainstream distribution of cannabidiol (CBD) across the United States is set to have a major impact on the sales of these products leading to a $20B market by 2024. Dispensary sales are projected to reach $5.3B, while general retail sales will make up $12.6B, and pharmacy sales will hit $2.2B, according to CBD: Cannabinoids Escape the Dispensary, a new report from Arcview Market Research and BDS Analytics.

The #1 cited market research for the cannabis industry. (PRNewsfoto/The ArcView Group)

Consumers first learned of THC's non-psychoactive cousin ? CBD ? from dispensaries in states with legal cannabis programs. In recent years, however, general retailers have taken notice of the compound's popularity and have looked to capitalize on its ambiguous legal standing. The report forecasts that the vast majority of CBD sales will take place in general retail distribution channels by 2024.

"CBD products on the shelves of grocery stores and mass merchants is just the first act in the "Cannabinoids Everywhere" phenomenon," said Troy Dayton, CEO of the Arcview Group. "Unlike with alcohol, coffee or other plant-sourced consumables, cannabis product marketers have more than taste and strength to work with; they also have the subtle effects of 100-plus cannabinoids other than THC. The popularity of CBD is the first inkling of things to come."

"The FDA's approval of Epidiolex to treat childhood epilepsy conditions Dravet Syndrome and Lennox Gastaut Syndrome prompted our reassessment of CBD's potential as a functional ingredient," said Tom Adams, Managing Director and Principal Analyst for BDS Analytics' Industry Intelligence group and Editor-in-Chief for Arcview Market Research. "The 2018 Farm Bill's legalization of hemp cultivation and the subsequent moves by several states to push ahead without the FDA's approval of CBD as a food additive or supplement made it clear just how fast the market is likely to grow."

Other key trends analyzed in CBD: Cannabinoids Escape the Dispensary include:

The 38-page report is available for $297, or as part of the annual Cannabis Intelligence Briefing Series subscription service from Arcview Market Research and BDS Analytics, priced at $1,975. Visit shop.bdsanalytics.com to make your purchase today.

About Arcview Market Research:
Since 2011, Arcview Market Research has published over 20 reports analyzing and forecasting the rapidly evolving cannabis space. Arcview's flagship annual report, The State of Legal Cannabis Markets has become the industry standard for market analysis and data in the sector. In 2017, Arcview Market Research partnered with BDS Analytics to add more robust point-of-sale data and consumer insights to its offerings.  Arcview Market Research is a project of The Arcview Group.  Founded in 2010, Arcview is responsible for a number of groundbreaking ventures in the cannabis industry. The Arcview Investor Network includes more than 600 accredited investors who have put more than $260 million behind 200+ companies. In 2015 Arcview became a partner in CanopyBoulder, the first seed-stage mentor-driven business accelerator.  Arcview is also co-founder of Cannasure Insurance Services, the leading provider of business insurance to the cannabis industry.  Forbes Magazine recently named Arcview among the top 5 financial firms in the cannabis sector. Arcview's next invitation-only investor forum will take place in New York City October 2-4

About BDS Analytics:
Headquartered in Boulder, Colo., BDS Analytics provides businesses with comprehensive, actionable, and accurate cannabinoid market intelligence and consumer research. The company provides a holistic understanding of the cannabinoid market by producing insights from tracking and categorizing millions of individual consumer transactions, extensive and detailed consumer research and generating market-wide cannabinoid industry financial projections, all delivered through its market-leading GreenEdgetm platform. To learn more about how you can utilize BDS Analytics' industry-leading market research, please visit www.bdsanalytics.com.

Media Contact:
Dean Lee
The Arcview Group
[email protected]


 

SOURCE The Arcview Group


These press releases may also interest you

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....



News published on and distributed by: